The Weight Loss Tool That Could Help Nearly 1.9 Billion People August 25, 2021 - Baystreet.ca The obesity epidemic is still bursting at the seams. At the moment, 1.9 billion people are overweight, with more than 650 million considered obese. In addition, by 2022, $245 billion will be spent on products and services battling the issue. All according to NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), which is one of two companies working to develop psilocybin into a prescription drug for weight management. After all, psilocybin activates serotonin receptors, or "nature's own appetite suppressant," says Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight." In short, we could be looking at a massive game-changer for a multi-billion-dollar weight management market. Other companies that are working with psilocybin for a host of mental issues include Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), Optimi Health Corp. (CSE:OPTI)(OTC:OPTHF), and Field Trip Health Ltd. (TSX:FTRP)(NASDAQ:FTRP). Look at NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) NeonMind Biosciences, for example is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite. In addition, the company just announced that its common shares listed on the OTCQB under the symbol “NMDBF” are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States. The DTC is a subsidiary of the Depository Trust & Clearing Corporation that manages the electronic clearing and settlement of publicly traded companies in the United States. Securities that are eligible to be electronically cleared and settled through DTC are considered to be "DTC eligible." The electronic method of clearing securities through the DTC allows for cost-effective clearing and guaranteed settlement, simplifying and accelerating the settlement process for investors trading the Company’s shares. "By receiving DTC eligibility, NeonMind's common shares are more accessible to a broader range of potential investors,” said Rob Tessarolo, President and CEO of NeonMind. “Being DTC eligible simplifies the process of transferring the Company's shares between brokerages in the United States and speeds up the execution of trades, which should help to increase the liquidity of our stock. This is an important step as we continue to advance our business efforts and broaden awareness for our company in both domestic and international markets.” Other related developments from around the markets include: Cybin Inc. announced that it has filed two additional international patent applications that bring the potential to obtain patent coverage in 153 countries for each of the patent applications. The application, governed by the Patent Cooperation Treaty, grants the Company the right to file future national applications into treaty member jurisdictions, including important potential markets for the Company. The PCTs claim a library of phenethylamine and derivative drug development candidates and methods of use. Mind Medicine Inc. has joined the Critical Path Institute’s Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. C-Path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge sharing to spur innovation. MindMed will participate in C-Path’s PRO Consortium, contributing to its collaborative framework for qualification of clinical outcome assessments (COAs) for use as efficacy endpoint measures in clinical trials. Optimi Health Corp., as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant to key elements of psychedelic research. Mr. Simon specializes in gaining site and product licenses and related commercialization pathway development efforts. He has served in a variety of managerial and consulting roles overseeing quality assurance and regulatory affairs with direct involvement with the FDA and Health Canada audits relevant to medical device manufacturing, drug manufacturing and testing, drug and device establishments and clinical trial site implementation. Field Trip Health Ltd. reported its fiscal first quarter 2022 results for the three months ended June 30, 2021. During the fiscal first uarter, Field Trip continued to execute on its FT-104 drug development strategy, the buildout of a globally recognized brand of psychedelic-assisted therapy sites and development of its digital tools “Trip” and “Portal”. With the signing of leases for 5 new Field Trip Health centers during the quarter and an additional 3 subsequently, the Company significantly ramped its operations in order to position it as an early mover in the emerging psychedelics industry. Despite the continuing impact of the COVID-19 pandemic and its variants on operations, the Company believes that interest in, and demand for, psychedelic therapies will continue to rapidly expand over the coming years. The Company anticipates an increase in long-term demand for its depression related psychedelic therapies as case counts start to diminish in the future. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Please click here for full disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com
The Weight Loss Tool That Could Help Nearly 1.9 Billion People August 25, 2021 - Baystreet.ca The obesity epidemic is still bursting at the seams. At the moment, 1.9 billion people are overweight, with more than 650 million considered obese. In addition, by 2022, $245 billion will be spent on products and services battling the issue. All according to NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), which is one of two companies working to develop psilocybin into a prescription drug for weight management. After all, psilocybin activates serotonin receptors, or "nature's own appetite suppressant," says Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight." In short, we could be looking at a massive game-changer for a multi-billion-dollar weight management market. Other companies that are working with psilocybin for a host of mental issues include Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), Optimi Health Corp. (CSE:OPTI)(OTC:OPTHF), and Field Trip Health Ltd. (TSX:FTRP)(NASDAQ:FTRP). Look at NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) NeonMind Biosciences, for example is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite. In addition, the company just announced that its common shares listed on the OTCQB under the symbol “NMDBF” are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States. The DTC is a subsidiary of the Depository Trust & Clearing Corporation that manages the electronic clearing and settlement of publicly traded companies in the United States. Securities that are eligible to be electronically cleared and settled through DTC are considered to be "DTC eligible." The electronic method of clearing securities through the DTC allows for cost-effective clearing and guaranteed settlement, simplifying and accelerating the settlement process for investors trading the Company’s shares. "By receiving DTC eligibility, NeonMind's common shares are more accessible to a broader range of potential investors,” said Rob Tessarolo, President and CEO of NeonMind. “Being DTC eligible simplifies the process of transferring the Company's shares between brokerages in the United States and speeds up the execution of trades, which should help to increase the liquidity of our stock. This is an important step as we continue to advance our business efforts and broaden awareness for our company in both domestic and international markets.” Other related developments from around the markets include: Cybin Inc. announced that it has filed two additional international patent applications that bring the potential to obtain patent coverage in 153 countries for each of the patent applications. The application, governed by the Patent Cooperation Treaty, grants the Company the right to file future national applications into treaty member jurisdictions, including important potential markets for the Company. The PCTs claim a library of phenethylamine and derivative drug development candidates and methods of use. Mind Medicine Inc. has joined the Critical Path Institute’s Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. C-Path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge sharing to spur innovation. MindMed will participate in C-Path’s PRO Consortium, contributing to its collaborative framework for qualification of clinical outcome assessments (COAs) for use as efficacy endpoint measures in clinical trials. Optimi Health Corp., as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant to key elements of psychedelic research. Mr. Simon specializes in gaining site and product licenses and related commercialization pathway development efforts. He has served in a variety of managerial and consulting roles overseeing quality assurance and regulatory affairs with direct involvement with the FDA and Health Canada audits relevant to medical device manufacturing, drug manufacturing and testing, drug and device establishments and clinical trial site implementation. Field Trip Health Ltd. reported its fiscal first quarter 2022 results for the three months ended June 30, 2021. During the fiscal first uarter, Field Trip continued to execute on its FT-104 drug development strategy, the buildout of a globally recognized brand of psychedelic-assisted therapy sites and development of its digital tools “Trip” and “Portal”. With the signing of leases for 5 new Field Trip Health centers during the quarter and an additional 3 subsequently, the Company significantly ramped its operations in order to position it as an early mover in the emerging psychedelics industry. Despite the continuing impact of the COVID-19 pandemic and its variants on operations, the Company believes that interest in, and demand for, psychedelic therapies will continue to rapidly expand over the coming years. The Company anticipates an increase in long-term demand for its depression related psychedelic therapies as case counts start to diminish in the future. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Please click here for full disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com